This is an up to date summary of a recent review we carried out of the medical literature concerning Safinamide using the PubMed medical database :
Trade names : Xadago
Pharmacology : Safinamide has both dopaminergic properties (highly selective and reversible inhibition of monoamine oxidase-B) and non-dopaminergic properties (selective sodium channel blockade and calcium channel modulation, with consequent inhibition of excessive glutamate release) . It is intended to be added to the use of L-dopa or dopamine agonists.
Efficacy : In once daily dosages of 50mg to 100mg, after six months, Safinamide improved Parkinson's Disease symptoms and reduced "off" time when added to existing Parkinson's Disease treatments. However, the reduction in "off" time in comparison to a placebo was minimal. The increase in "on" time beyond that of a placebo was only 40 minutes for 50mg safinamide, and 50 minutes for 100mg safinamide. Higher dosages had no beneficial effects [2, 3, 4]. People taking daily dosages of 100 mg had a lower need for increased dopamine agonists .
Adverse effects : The side effects of safinamide were not disclosed. After 24 months, the improvement in dyskinesia was not statistically significant [2, 3].
 Drugs  75 (6) : 705-711 (E.D.Deeks)
 Movement Disorders  27 (1) : 106-112 (F.Stocchi, R. Borgohain, M.Onofrj, A.H.Schapira, M.Bhatt, V.Lucini, R.Giuliani, R. Anand)
 Movent Disorders  29 (10) : 1273-1280 (R.Borgohain, J. Szasz, P.Stanzione, C.Meshram, M.H.Bhatt, D.Chirilineau, F.Stocchi, V.Lucini, R.Giuliani, E.Forrest, P.Rice, R.Anand)
 Journal of Parkinsons Disease  Jan 29 [Epub ahead of print] (C.Cattaneo, M.Sardina, E.Bonizzoni)
 European Journal of Neurology  20 (2) : 271-280 (A.H. Schapira, F.Stocchi, R.Borgohain, M.Onofrj, M.Bhatt, P.Lorenzana, V. Lucini, R.Giuliani, R.Anand)